Kiora Pharmaceuticals, Inc.

NasdaqCM KPRX

Kiora Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2024: 12,779,177

Kiora Pharmaceuticals, Inc. Shares (Diluted, Weighted) is 12,779,177 for the Trailing 12 Months (TTM) ending September 30, 2024, a 263.65% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Kiora Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2023 was 3,514,153, a 699.46% change year over year.
Kiora Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2022 was 439,567, a 133.85% change year over year.
Kiora Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2021 was 187,970, a 81.23% change year over year.
Kiora Pharmaceuticals, Inc. Shares (Diluted, Weighted) for the Trailing 12 Months (TTM) ending September 30, 2020 was 103,718, a 24.98% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

NasdaqCM: KPRX

Kiora Pharmaceuticals, Inc.

CEO	Dr. Brian M. Strem Ph.D.
IPO Date	Feb. 13, 2015
Location	United States
Headquarters	1371 East 2100 South
Employees	12
Sector	Health Care
Industries Pharmaceuticals Cosmetics Eyewear

Description

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, as well as for treating non-infectious posterior uveitis; and KIO-201, an eye drop, which is in Phase 3 clinical trial for treating patients undergoing PRK surgery for corneal wound repair after refractive surgery. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.

Key trends

Past 5 years